CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-07-24). The draft was written by AI, the existence of all 2 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.6.
Verdict No. 1784 · Search date 2026-07-24 · Methodology v0.6

Cognitive behavioral therapy,
does it really help with Reduced panic-disorder severity and improved treatment response?

30-Second Summary
B
Evidence Grade B · 68 · Safety unknown
CBT improved the PDSS result, while the co-presented CGI result was null
What the
research shows
The grade is B. Barlow 2000 randomized 326 patients; the 312-person analysis population reflected exclusions for ineligibility and blinding problems. PDSS and CGI were both main outcomes. PDSS response succeeded at 48.7% with CBT versus 21.7% with pill placebo, P=.03, and maintenance response was 39.5% versus 13.0%, P=.02. Acute CGI response was nonsignificant at 53.9% versus 37.5%. Pill-placebo control is a design strength compared with verdict 1782, which is B with 70 points, but psychotherapy cannot be fully blinded, preventing A.
What the
ads claim
Promotion can promise rapid elimination of all panic attacks and permanent relapse prevention. Response varied by measure and time, some patients dropped out or did not respond, and skilled exposure-based delivery matters.
*

Useful facts when choosing a product

  • The trial CBT combined interoceptive exposure, cognitive restructuring, and breathing retraining in eleven sessions over twelve weeks.
  • Acute responders received six additional monthly maintenance sessions.
  • Interoceptive exposure can temporarily increase anxiety, so medical mimics and acute psychiatric risk should be assessed.
Gap Measurement · Verdict 1784 · B 68
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

Barlow et al. randomized 326 patients across five groups; the 312-person analysis population reflected exclusions for ineligibility and blinding problems. PDSS and CGI were both main outcomes. PDSS response favored CBT over placebo and remained positive at maintenance, while acute CGI response was nonsignificant. NIMH provided public grant funding and Teva supplied imipramine and matching placebo. The Pompoli Cochrane review quantitatively analyzed 54 trials with 3,021 participants and supported psychological therapy while noting bias and uncertainty between therapies.

02

Why this is classified as B (68)

The PDSS main outcome succeeded in the 312-person analysis population reflecting eligibility and blinding exclusions; pill-placebo control, maintenance response, and replicated trials support B. The co-presented CGI main outcome was null, and inability to blind therapy plus limited generalizability yield 68 points.

Counterpoint. The PDSS main outcome succeeded, but the co-presented acute categorical CGI main outcome was null.

Rejudgment record. Cross-check applied — Distinguished 326 randomized from the 312-person analysis population reflecting eligibility and blinding exclusions, and considered the successful PDSS and null CGI main outcomes together

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
Reduced panic-disorder severityBThe continuous PDSS main outcome and PDSS response succeeded versus placebo.
Improved six-month maintenance responseBPDSS maintenance response was 39.5% versus 13.0%, P=.02.
Improved acute categorical CGI responseDThe contrast of 53.9% versus 37.5% was not statistically significant.

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Barlow DH et al. 2000Multicenter randomized pill-placebo and active-controlled trial312Public United States NIMH grants MH45963 through MH45966 and MH00416; Teva supplied drug and matching placeboMain outcomes of continuous PDSS and categorical CGI responsePDSS response succeeded at 48.7% versus 21.7%, P=.03; acute CGI response of 53.9% versus 37.5% was nonsignificant.Pivotal public-funded placebo-controlled randomized trial
Pompoli A et al. 2016 CochraneNetwork meta-analysis of randomized psychotherapy trials3,021Academic Cochrane review with no dedicated manufacturer fundingShort-term response, remission, dropout, and long-term effectsSupported response and remission with CBT approaches, while comparative evidence between therapies was low or very low quality.Supportive replication and generalizability evidence
§

Receipt — 2 References

All 2 cited sources were verified for existence at the original page (as of 2026-07-24).

Barlow DH, Gorman JM, Shear MK, Woods SW. Cognitive-Behavioral Therapy, Imipramine, or Their Combination for Panic Disorder: A Randomized Controlled Trial. JAMA. 2000;283(19):2529-2536. PMID: 10815116. DOI: 10.1001/jama.283.19.2529.
checked
Pompoli A, Furukawa TA, Imai H, Tajika A, Efthimiou O, Salanti G. Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis. Cochrane Database Syst Rev. 2016;2016(4):CD011004. DOI: 10.1002/14651858.CD011004.pub2.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-24 · Corrections: none

Cite this verdict

Cognitive behavioral therapy x symptoms and response in panic disorder Evidence Grade B card
[Chamgap] Cognitive behavioral therapy x symptoms and response in panic disorder — Evidence Grade B·68. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/mood/cognitive-behavioral-therapy-panic-disorder-response/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.